Efficacy and safety of WBRT+EGFR-TKI versus WBRT only in the treatment of NSCLC patients with brain metastasis: An updated meta-analysis

Kai Zhou† | Xiaoping Cai† | Xiaoqiu Wang | Xiang Lan | Xuexia Zhang

1Department of Neurology, Ningbo Medical Center Lihuili Hospital, Ningbo, China
2Department of Respiratory and ICU, Lishui People’s Hospital, Lishui, China
3Department of Oncology, Lishui People’s Hospital, Lishui, China
4Department of Radiology, Lishui People’s Hospital, Lishui, China
5Department of Medicine, Lishui People’s Hospital, Lishui, China

Correspondence
Xuexia Zhang, Department of Medicine, Lishui People’s Hospital, Lishui Zhejiang Province 323000, China.
Email: zhangbaobao211103@163.com

Funding information
Medical and health science and technology, Grant/Award Number: 2020ky1076

Abstract

Background: To investigate the efficacy and safety of whole brain radiotherapy (WBRT) combined with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) versus WBRT only in the treatment of brain metastasis in non-small cell lung cancer (NSCLC) patients by pooling open published data.

Methods: Prospective clinical studies relevant to WBRT+EGFR-TKI versus WBRT only in the treatment of NSCLC brain metastasis were electronically searched in the Pubmed, EMBase, Cochrane, Wangfang, CNKI and Google scholar databases. The treatment response, 1-year survival and treatment-associated toxicity were pooled and expressed by odds ratio (OR) under a fixed or random effect model. The publication bias was evaluated by Begg’s funnel plot and Egger’s line regression test.

Results: Eighteen prospective clinical studies were included in the study. The combined results indicated that the objective response rate (ORR) in the WBRT+TKI group was superior to WBRT only with a statistical difference (OR = 2.67, 95% CI: 2.10–3.38, p < 0.05) under a fixed effect model. Ten studies reported the 1-year survival rate between the WBRT+TKI and WBRT only groups. The combined results showed that 1-year survival rate in the WBRT+TKI group was higher than that of the WBRT only group with a statistical difference (OR = 2.70, 95% CI: 1.95–3.74, p < 0.05). For treatment-associated toxicity, the combined data indicated that the treatment-related rash in the WBRT+TKI group was significantly higher than that of the WBRT only group with a statistical difference (OR = 2.72, 95% CI: 1.53–4.84, p < 0.05). However, the incidence of nausea/vomiting (OR = 0.84, 95% CI: 0.60–1.17, p > 0.05), diarrhea (OR = 1.31, 95% CI: 0.83–2.07, p > 0.05), fatigue (OR = 1.40, 95% CI: 0.70–2.81, p > 0.05) and myelosuppression (OR = 0.86, 95% CI: 0.56–1.32, p > 0.05) were not statistically different between the two groups.

Conclusions: Based on the current publications, WBRT+EGFR-TKI can improve the treatment response and 1-year survival rate but not increase the toxicity except for rash compared to WBRT alone in the treatment of brain metastasis in NSCLC patients.

Keywords
epidermal growth factor receptor-tyrosine kinase inhibitor, meta-analysis, non-small cell lung cancer, whole brain radiotherapy
INTRODUCTION

Lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is known globally as one of the leading causes of malignant tumor-associated death.\(^1\) It has previously been reported that most NSCLC (75\%) cases are at an advanced stage when first diagnosed and the opportunity of surgery as a result of metastatic brain disease has been lost.\(^2\)

The general prognosis for NSCLC patients with metastatic brain disease is poor with an extremely low long-term survival rate.\(^3\) At present, whole brain radiotherapy (WBRT) is generally used for controlling metastatic lesions of the brain in NSCLC patients, especially those patients with multiple brain lesions.\(^4\) However, the treatment response or prognosis of patients with metastatic brain disease is unsatisfactory with a median survival time of 3–6 months. Therefore, improving the treatment efficacy of NSCLC patients with brain metastasis is important in order to improve their overall survival.\(^5\)

Tyrosine kinase inhibitors (TKIs) are small molecular targeted drugs that can inhibit tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib and gefitinib, are commonly clinically used in the treatment of patients with advanced NSCLC, especially those with \(EGFR/KRAS\) mutation. Several studies have previously evaluated the efficacy and safety of \(WBRT+\) EGFR-TKI versus WBRT only in brain metastasis cases of NSCLC.\(^6,7\) However, the conclusion of these studies was different due to different treatment modality and patients clinical heterogeneity. Therefore, we performed this meta-analysis to further evaluate the efficacy and safety of \(WBRT+\) EGFR-TKI versus WBRT only in the treatment of brain metastasis of NSCLC with an up-to-date meta-analysis.

METHODS

Identification of studies via electronic databases

Prospective clinical studies on the efficacy and safety of \(WBRT+\) EGFR-TKI versus WBRT only in the treatment of NSCLC patients with brain metastasis were electronically searched in the Pubmed, EMBase, Cochrane, Wangfang, CNKI and Google scholar databases. The electronic database searching words were: Epidermal growth factor receptor-tyrosine kinase inhibitors/EGFR-TKI, lung cancer, carcinoma of the lung, non-small cell lung cancer, whole brain radiotherapy/WBRT, and gefitinib, erlotinib. The references of the identified studies were also reviewed to determine potentially suitable publications.

Study inclusion and exclusion criteria

Inclusion criteria: (i) Prospective clinical studies relevant to \(WBRT+\) EGFR-TKI versus WBRT only in the treatment of NSCLC patients with brain metastasis. (ii) Patients included in original studies were those with NSCLC confirmed by

---

**FIGURE 1** Flow-chart of electronic searching and inclusion procedure of studies included
| Studies       | Year | Sample size | Age | Treatment                  | WBRT only Sample size | Age | Treatment                  | Outcome                                      | EGFR mutation |
|--------------|------|-------------|-----|----------------------------|-----------------------|-----|----------------------------|----------------------------------------------|---------------|
| Cai et al.6  | 2013 | 65          | Na  | WBRT + erlotinib/gefitinib | 92                    | Na  | Whole brain radiotherapy   | ORR, 1-year survival, toxicity               | 27.4%         |
| Zhuang et al.7 | 2013 | 23          | 60  | WBRT                       | 31                    | 63  | WBRT                       | ORR                                           | 20.4%         |
| Fu et al.8   | 2012 | 38          | 56  | Radiotherapy + gefitinib   | 123                   | 56  | Radiotherapy               | ORR, 1-year survival, toxicity               | Na            |
| Zhang9       | 2014 | 20          | 52  (32–78) | Radiotherapy + gefitinib/erlotinib | 27             | 51  (33–75) | Radiotherapy               | ORR, 1-year survival, toxicity               | Na            |
| Yi & Qin10   | 2012 | 21          | Na  | Radiotherapy + gefitinib   | 21                    | Na  | Radiotherapy               | ORR, DCR, toxicity                           | Na            |
| Xiao et al.11| 2011 | 24          | Na  | 3D-CRT + gefitinib         | 22                    | Na  | 3D-CRT                     | ORR, DCR, toxicity                           | Na            |
| Wu et al.12  | 2012 | 35          | Na  | WBRT + gefitinib           | 18                    | Na  | WBRT                       | ORR, 1-year survival rate                    | Positive      |
| Liu13        | 2013 | 52          | 54  (28–74) | WBRT/3D-CRT + erlotinib   | 52                    | 51  (30–72) | WBRT/3D-CRT               | ORR, DCR, toxicity, PFS                      | Positive      |
| Liu et al.14 | 2015 | 35          | 75.8 (65–80) | Radiotherapy + gefitinib  | 35                    | 74.8 (65–80) | Radiotherapy               | ORR, DCR, toxicity                           | Nm            |
| Zou et al.15 | 2016 | 30          | 64.12 (20–70) | WBRT + gefitinib          | 30                    | 64.32 (22–7)  | WBRT                       | ORR, DCR, KPS, 1-year survival, toxicity    | Positive      |
| Liang et al.16| 2017 | 35          | 52.5 (45–60) | WBRT + erlotinib          | 35                    | 61.5 (55–68) | WBRT                       | ORR, DCR, toxicity                           | Positive      |
| Yuan et al.17| 2017 | 23          | 58.4 (45–73) | WBRT + erlotinib          | 23                    | 58.5 (44–72) | WBRT                       | ORR, DCR, 1-year survival, toxicity         | Na            |
| Yang18       | 2017 | 40          | 59.4 (43–75) | WBRT + erlotinib          | 40                    | 59.8 (45–73) | WBRT                       | ORR, DCR, 1-year survival                   | Mixed         |
| Lu19         | 2018 | 45          | 67.45 (52–83) | WBRT/3D-CRT + erlotinib  | 45                    | 68.06 (55–85) | WBRT/3D-CRT               | ORR, DCR, 1-year survival                   | Na            |
| Xu et al.20  | 2018 | 31          | 54.47 (36–69) | WBRT + gefitinib         | 30                    | 53.52 (35–70) | WBRT                       | ORR, DCR, toxicity                           | Positive      |
| An et al.21  | 2020 | 30          | 39–78 | WBRT + gefitinib         | 30                    | 39–78 | WBRT                       | ORR, DCR, toxicity                           | Na            |
| Shen22       | 2021 | 36          | 57.43 (35–67) | WBRT + gefitinib        | 36                    | 58.52 (37–64) | WBRT                       | ORR, DCR, toxicity                           | Na            |
| Liang23      | 2021 | 41          | 68.2 (41–82) | WBRT + erlotinib         | 41                    | 68.9 (53–83) | WBRT                       | ORR, DCR, toxicity, 1-year survival         | Na            |
pathology or cytology. (iii) Studies were published in English or Chinese. (iv) Brain metastasis was confirmed by CT or MRI. (v) Treatment associated response and toxicity could be extracted from the original studies.

Exclusion criteria: (i) Review or case report relevant to WBRT + EGFR-TKI or WBRT in the treatment of NSCLC patients with brain metastasis. (ii) Animal studies. (iii) Brain metastases of other carcinoma not NSCLC. (iv) Studies without enough data to calculate the ORR or treatment toxicity.

Data and information extraction

Two researchers independently reviewed the studies and extracted the data. If there were different opinions in data extraction, a third reviewer was consulted to discuss the divergence and make a final decision. The information extracted from the study included: (1) general data: author’s name, publication date and author’s country, and (2) literature features: number of cases, median age, EGFR mutation status, treatment methods and outcome indicators in the WBRT + EGFR-TKI
and the WBRT only group. The corresponding authors would be contacted by e-mail if the required data could not be obtained. If the required data could not be obtained finally, it would be recorded as “not available/Na”.

**Publication bias evaluation**

The publication bias was evaluated by Begg’s funnel plot and Egger’s line regression test. If the funnel plot was left-right symmetrical and Egger’s test \( p > 0.05 \), the publication bias was considered as not significant.

**Statistical analysis**

STATA11.0 statistical software (http://www.stata.com) was used for data pooling. The treatment response was demonstrated by objective response rate (ORR) and calculated by
the equation of ORR = complete response (CR) + partial response (PR). The ORR and treatment associated toxicity was expressed by odds ratio (OR) and corresponding 95% confidence interval (95% CI). The statistical heterogeneity across the included 18 studies was investigated by I² test. Publication bias was assessed by Begg’s funnel plot and Egger’s line regression test (Figure 1).

RESULTS

Main features of included studies

After removing unsuitable publications, 18 prospective clinical studies were included for clinical data combination. The general features of the studies included are shown in Table 1.

Combined objective response rate between WBRT+TKI and WBRT only groups

All the 18 studies reported a response rate between the WBRT+TKI and WBRT only groups. The combined result indicated that ORR in the WBRT + TKI group was superior to WBRT only with a statistical difference (OR = 2.67, 95% CI: 2.10–3.38, p < 0.05) under a fixed effect model, Figure 2.

1-year survival analysis between WBRT+TKI and WBRT only groups

Ten studies reported the 1-year survival rate between the WBRT+TKI and WBRT only groups. The data was combined under a fixed effect mode because of nonstatistical heterogeneity (I² = 0.0%, p = 0.666). The combined results showed that the 1-year survival rate in the WBRT+TKI group was higher than that of the WBRT only group with a statistical difference (OR = 2.70, 95% CI: 1.95–3.74, p < 0.05), Figure 3.

Treatment-related toxicity between WBRT +TKI and WBRT only groups

The combined results demonstrated that the treatment-related rash in the WBRT+TKI group was significantly higher than that of the WBRT only group with a statistical difference (OR = 2.72, 95% CI: 1.53–4.84, p < 0.05). However, the incidence of nausea/vomiting (OR = 0.84, 95% CI: 0.60–1.17, p > 0.05), diarrhea (OR = 1.31, 95% CI: 0.83–2.07, p > 0.05), fatigue (OR = 1.40, 95% CI: 0.70–2.81, p > 0.05) and myelosuppression (OR = 0.86, 95% CI: 0.56–1.32, p > 0.05) were not statistically different between the WBRT+TKI and WBRT only groups, Figure 4.

Publication bias

The funnel plot was left–right asymmetric which indicated an obvious publication bias. The Egger’s line regression test also showed statistical publication bias (p < 0.05), Figure 5.

DISCUSSION

Brain metastasis in NSCLC patients is common. About 30%–50% of patients with NSCLC will eventually develop brain metastasis leading to neurological dysfunction which seriously reduces their quality of life. The prognosis of NSCLC patients with brain metastatic lesions is extremely poor with a median survival time of 3–6 months. Therefore, how to determine effective treatment methods in lung cancer patients with brain metastasis is important in order to improve their prognosis. It has been reported that the prognosis of brain metastatic driver gene positive NSCLC cases can be significantly improved by gene detection and targeted drug treatment. Lung cancer driver genes usually include epidermal growth factor receptors (EGFRs), anaplastic lymphoma kinase (ALK), ROS1 fusion, HER2 mutation, BRAF mutation, neurotrophic tyrosine receptor kinase (NTRK) fusion, etc.

In recent years, with the rapid development of precision medicine, targeted drugs associated with the aforementioned driver genes play an important role in improving the prognosis of NSCLC patients with brain metastasis. The most applied targeted drugs for patients with advanced NSCLC include epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), such as gefitinib and erlotinib. EGFR targeted drugs are small molecule drugs of erlotinib and gefitinib which can pass through the blood–brain barrier and can be used in the treatment of NSCLC patients with
brain metastasis. For NSCLC patients with brain metastasis and EGFR mutation, the ORR has been reported to be about 60% with a median OS of 13 months, and median PFS of 11.7 months.24,25

Several studies have indicated that WBRT plus target drugs may have potential survival benefit for improving the treatment response and long-term survival of NSCLC cases with brain metastasis.6 However, the conclusion of these studies was different due to the different treatment modalities and clinical heterogeneity of patients. In the present study, we pooled the treatment response and toxicity of the 18 studies included and found the ORR and 1-year survival rate in the WBRT+TKI group was higher than that of the WBRT only group with a statistical difference ($p < 0.05$). However, the treatment-associated toxicity of a rash in the WBRT+TKI group was significantly higher than that of the WBRT only group ($OR = 2.72$, 95% CI: 1.53–4.84, $p < 0.05$). This study indicates that based on current publications, WBRT+EGFR-TKI can improve the treatment response and 1-year survival rate but not increase the toxicity except for a rash, compared with WBRT alone in NSCLC patients with brain metastasis.

In conclusion, WBRT combined with EGFR-TKIs for NSCLC patients with brain metastasis is better than WBRT only. WBRT+EGFR-TKIs can improve the treatment response and 1-year survival rate, but does not increase the treatment toxicity, except for rash. However, there are also deficiencies in the meta-analysis such as the small samples in each study included, clinical heterogeneity (age of the included cases, treatment modality, gene mutations) language restriction and publication bias. Therefore, the conclusions should be further validated by well-designed multiple center clinical trials.

ACKNOWLEDGMENT
This work was supported by medical and health science and technology project of Zhejiang Province (no.2020ky1076).

CONFLICT OF INTEREST
The authors confirm that there are no conflicts of interest.

ORCID
Xuexia Zhang (https://orcid.org/0000-0002-2290-3871

REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2021;71(3):209–49.
2. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.
3. Lee K, Choi YJ, Kim JS, et al. Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications. Thorac Cancer. 2021;12(15):2143–50.
4. Olmez I, Donahue BR, Butler JS, Huang Y, Rubin P, Xu Y. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung Cancer. 2010;70(2):174–9.
5. Ou SI, Zhu VW. CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome. Lung Cancer. 2019;130:201–7.
6. Cai Y, Wang JY, Liu H. Clinical observation of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer patients with chemotherapy failure. Asian Pac J Cancer Prev. 2013;14(10):5699–703.
7. Zhuang H, Yuan Z, Wang J, Zhao L, Pang Q, Wang P. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Des Devel Ther. 2013;7:1179–86.
8. Fu H, Zhang XL, Xiao Y, Liu XJ, Long C, Hu YD. Evaluation of gefitinib plus radiotherapy in non-small-cell lung cancer patients with brain metastases. Zhonghua Yi Xue Za Zhi. 2012;92(8):524–7.
9. Zhang F. Therapeutic effect of EGFR TKIs combined with whole brain radiotherapy versus whole brain radiotherapy on brain metastasis of lung adenocarcinoma. China Med Eng. 2014;22(12):71–2.
10. Yi SY, Qin YC. Clinical efficacy of gefitinib combined with whole brain radiotherapy in the treatment of brain metastasis of non-small cell lung cancer. J North China Coal Med Univ. 2012;14(6):831–2.
11. Xiao Y, Liu YL, Wang HB, Fang F, Chen H, Wang RL. Efficacy of three-dimensional conformal radiotherapy combined with gefitinib in the treatment of elderly non-small cell lung cancer with brain metastasis. Chin J Gerontol. 2011;31(10):1767–8.
12. Wu TA, Lin DR, Wang ZH, Peng Y. Effects of gefitinib combined with whole brain radiation on brain metastasis from non-small-cell lung cancer. Chin J Gen Pract. 2012;10(06):893–5.
13. Liu P. Clinical observation of epidermal growth factor receptor tyrosine kinase inhibitor combined with radiotherapy in the treatment of brain metastasis of non-small cell lung cancer. J Chin Pract Diagn Ther. 2013;27(07):693–4.
14. Liu DD, Zhou F. Radiotherapy combined with gefitinib in the treatment of elderly non-small cell lung cancer. J Guangxi Med Univ. 2016;33(01):122–4.
15. Zou JF, Jiang T. Efficacy of ivermectin combined with whole brain radiation therapy for non-small-cell lung cancer with brain metastases. Pract J Cancer. 2016;31(12):2008–10.
16. Liang XB, Zhang YH, Zhang YL, Wang Y, Zhang WZ. Erlotinib combined with whole brain radiotherapy for brain metastasis of non-small cell lung cancer. Mod Diagn Treat. 2017;28(10):1826–7.
17. Yuan G, Hao LF. Clinical effect of erlotinib combined whole brain radiotherapy (WBRT) in patients with brain metastases of non-small-cell lung cancer (NSCLC). J Dis Monitor & Control. 2017;11(11):890–1.
18. Yang ML. Efficacy of erlotinib combined with whole brain radiotherapy for brain metastasis of non-small cell lung cancer. Chin J Clin Ration Drug Use. 2017;10(23):44–5.
19. Lu AL. Erlotinib combined with whole brain radiotherapy for non-small cell lung cancer with brain metastasis and its prognosis. Chin J New Clin Med. 2018;11(02):183–5.
20. Xue BX, Geng L, Kuang XK, Guo SM, Ma D, Pang JF. Clinical observation of gefitinib combined with whole brain radiotherapy in the treatment of brain metastasis of non-small cell lung cancer. Guide China Med. 2021;19(09):77–8.
21. Liang J. The efficacy of radiotherapy (whole brain) combined with gefitinib plus radiotherapy in non-small-cell lung cancer patients with multiple brain metastases from lung adenocarcinoma. Drug Des Devel Ther. 2012;6:703–10.
22. Shen LH. Value of erlotinib combined with whole brain radiotherapy in the treatment of brain metastasis of non-small cell lung cancer. Chin J Pract Diagn Ther. 2013;14(10):5799–803.
23. Liang J. The efficacy of radiotherapy (whole brain) combined with gefitinib plus radiotherapy in non-small-cell lung cancer patients with multiple brain metastases from lung adenocarcinoma. Drug Des Devel Ther. 2013;7:1179–86.
25. Liu J, Xing L, Meng X, et al. Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation. Onco Targets Ther. 2016;9: 671–9.

26. Gu Y, Xu Y, Zhuang H, et al. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: appropriate timing and technique. Thorac Cancer. 2021; 12(23):3157–3168.

How to cite this article: Zhou K, Cai X, Wang X, Lan X, Zhang X. Efficacy and safety of WBRT +EGFR-TKI versus WBRT only in the treatment of NSCLC patients with brain metastasis: An updated meta-analysis. Thorac Cancer. 2022;13:563–70. https://doi.org/10.1111/1759-7714.14299